Scientific Research center Eco-Safety LLC
Saint Petersburg, 196143, Russia
NCT Number: NCT03213353
This is a single-dose, randomized, two-period cross-over study with 72 healthy male and female volunteers. The investigational products will be given (after fasting overnight) at separate visits separated by 7 ± 3 days. Blood for pharmacokinetic analyses will be drawn pre-dose and at 5, 10, 15, 20, 25, 30, 40, 60, 75, 90, 105 minutes, as well as 2, 2.25, 3, 4, 5, 6, 8, and 12 hours after drug administration. Subjects will also be monitored to capture any adverse events that may occur. Bioequivalence will be assessed based on the single-dose pharmacokinetics of paracetamol, guaifenesin and phenylephrine, respectively
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Saint Petersburg, 196143, Russia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
Other names: Benylin Cough & Cold All in One Relief Tablets
Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
Time frame: At baseline and during 12 hours after product administration
The maximum observed plasma concentration (Cmax)
Time frame: At baseline and during 12 hours after product administration
AUCt is defined as area under the plasma concentration versus time curves from start of drug administration until the last measureable concentration.
Time frame: At baseline and during 12 hours after product administration
AUC∞ is defined as area under the plasma concentration versus time curves from start of drug administration until the plasma concentration is negligible (infinity).
Time frame: From 12 hours after start of drug administration until up to 96 hours
AUCextrap is defined as area under the plasma concentration versus time curves from 12 hours until infinity
Time frame: At baseline and during 12 hours after product administration
Tmax is defined as the time point at which the maximum plasma concentration (Cmax) occurs
Time frame: At baseline and during 12 hours after product administration
The half-life i defined as the time taken for the plasma concentration to fall to half its original value
Time frame: At baseline and during 12 hours after product administration
The terminal elimination rate constant is the rate at which the drug is removed from the body system
Time frame: At baseline and during 12 hours after product administration
Mean residence time (MRT) is the average amount of time that a single molecule of drug stays in the body
Time frame: At baseline and during 12 hours after product administration
The maximum observed plasma concentration (Cmax)
Time frame: At baseline and during 12 hours after product administration
AUCt is defined as area under the plasma concentration versus time curves from start of drug administration until the last measureable concentration.
Time frame: At baseline and during 12 hours after product administration
AUC∞ is defined as area under the plasma concentration versus time curves from start of drug administration until the plasma concentration is negligible (infinity).
Time frame: From 12 hours after start of drug administration until up to 96 hours
AUCextrap is defined as area under the plasma concentration versus time curves from 12 hours until the plasma concentration is negligible (infinity).
Time frame: At baseline and during 12 hours after product administration
Tmax is defined as the time point at which the maximum plasma concentration (Cmax) occurs
Time frame: At baseline and during 12 hours after product administration
The half-life i defined as the time taken for the plasma concentration to fall to half its original value
Time frame: At baseline and during 12 hours after product administration
The terminal elimination rate constant is the rate at which the drug is removed from the body system
Time frame: At baseline and during 12 hours after product administration
Mean residence time (MRT) is the average amount of time that a single molecule of drug stays in the body
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
A SingleDose Rand, TwoPeriod, Crossover Bioequivalence Study Between a Combination Tablet With Paracetamol, Guaifenesin and Penylephrine HCL (Wrafton Lab Ltd, UK) and Vicks Active SymptoMax Plus, Powder for Oral Solution (Wrafton Lab Ltd, UK) in Healthy Adult Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06655194
Bioequivalence, Healthy Volunteers
Monterrey, Nuevo León, Mexico
View Trial DetailsNCT06778304
Bioequivalence, Healthy Volunteers
Chengdu, Sichuan, China
View Trial DetailsNCT01331993
Bioequivalence, Healthy Volunteers
London, United Kingdom
View Trial DetailsNCT07698288
Bioequivalence
Mexico City, Mexico
View Trial Details